Impact of National Comprehensive Cancer Network Guidelines Inclusion of Level 1 Evidence on Insurance Denial for Randomized Controlled Trial Patients with Metastatic Spine Disease
The inclusion of Level 1 evidence in the NCCN guidelines has resulted in a numerical halving of spine SBRT insurance denials on a RCT, with the small sample size likely the largest culprit of not meeting statistical significance. These findings illustrate the importance of generating high-quality evidence, followed by timely inclusion into the NCCN guidelines.
Authors
- Yilun Sun (ORCID: https://orcid.org/0000-0002-1341-382X)
- Ulysses Gardner (ORCID: https://orcid.org/0000-0003-4378-117X)
- Shearwood McClelland (ORCID: https://orcid.org/0000-0001-7951-9726)
- Raed Zuhour (ORCID: https://orcid.org/0000-0001-5537-6644)
- Daniel Eidelberg Spratt (ORCID: https://orcid.org/0000-0002-5973-4741)
- Melissa M Brately
Institutions
- University Hospitals Seidman Cancer Center (US)
- Johns Hopkins Hospital (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Reports of Practical Oncology & Radiotherapy
- Published
- 2024-12-04
- DOI
- https://doi.org/10.5603/rpor.102822
- Primary Topic
- Management of metastatic bone disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00